Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2831)	9/19/2011 5:13:58 PM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 3027

All dosage forms of Lovenox—both vials and syringes—have concentrations of 100mg/ml or 150mg/ml, so I don’t think Amphastar’s approval excludes any dosage forms.

To: tuck who wrote (2831)	9/20/2011 7:35:09 PM
From: mopgcw	Read Replies (1) \| Respond to of 3027

i haven't bought here yet. i thought about trying to play the bounce a bit, but chickened out. i figure, they had what $5/share cash in june. they make another $1+ this Q and what $0.75 in q4? gets you you to $6-$7 cash on hand. so $8-$9/share, i would add a little to my position. i agree with rk -- if it gets cheap enough, nvs munches them, and at $8 the platform/technology is free. i can't help but think this is an overreaction. it is not as though their sales will go to 0 is it? cut it in 1/2 and you still get $2/yr. a 5x = $10/share for that alone. so i am sitting still for the haul. seems like a good optionality. am i missing something? most likely i am. gambatte George